Evaluating clinical and laboratory effects of ozone in non-surgical periodontal treatment: a randomized controlled trial

Abstract

Objective: This study aims to evaluate the clinical and biochemical (oxidative stress and pro-inflammatory mediators) effects of the gaseous ozone use accompanied by scaling and root planning (SRP) in periodontal treatment. Material and Methods: The study population consisted of 40 patients with chronic periodontitis (CP) randomly sorted into two groups of 20. The experimental group received SRP plus 3 watts gaseous ozone in two separate applications five days apart, whereas the control group received SRP plus placebo. Clinical periodontal parameters were assayed and saliva samples were taken before the initial and one month after the second treatment. Periodontal examination assessed plaque index (PI), gingival index (GI), probing depth, and clinical attachment level (CAL). Total antioxidant status (TAS), total oxidant status (TOS), nitric oxide (NO), 8-hydroxy-2'-deoxyguanosine (8-OHdG), myeloperoxidase (MPO), glutathione (GSH), malondialdehyde (MDA), and transforming growth factor-beta (TGF-β) levels were evaluated from saliva samples. Results: Changes following treatment in PI, GI, probing depth, and CAL scores were similar for both groups (p>0.05). Of note, TGF-β levels were observed to be higher in the treatment group than in controls (p<0.05). Changes in 8-OHdG, TAS, TOS, NO, MPO, GSH and MDA levels, however, were not significantly different between groups (p>0.05). Conclusion: The findings of this study indicate that SRP plus gaseous ozone versus SRP alone does not correlate to a significant improvement in periodontal recovery.

Evaluation of the effect of topical and systemic ozone application in periodontitis: an experimental study in rats

“…Although there are several studies indicating that topical ozone application with nonsurgical periodontal treatment has no additional benefit in clinical periodontal parameters, 14 , 30 – 32 few studies have reported significant improvement in periodontal parameters in patients with periodontitis treated with scaling and root planing along with ozone application 15 , 16 . Erdemci, et al 21 (2014) evaluated the effect of SO and TO application after tooth extraction and measured mineralized and trabecular bone and osteoid and osteoblast surfaces for determining alveolar bone healing.…”

Ozonioterapia como coadjuvante no tratamento da periodontite: revisão de literatura

“…Os níveis glicêmicos dos pacientes já são correlacionados com a saúde e recuperação periodontal, tendo, ambas as doenças, uma correlação estabelecida (Zainal et al, 2021). Dengizek et al, (2019) afirma que o uso do ozônio não foi relevante quando comparado com a raspagem e alisamento coronário, isoladamente. Tal metodologia, no entanto, parece não compreender o uso da terapêutica como medida complementar ao tratamento mecânico.…”

“…Ademais, oito estudos de caráter clínico, também estabeleceram uma relação positiva com a terapia complementar. As formas de aplicação variaram, apresentando-se como nanobolhas (Hayakumo et al, 2013), óleo ozonizado (Nardi et al, 2020, Anzolin et al, 2020; água (R. Niveda, Sankari Malaiappan, 2019, Vasthavi., et al, 2019, Kaur., et al, 2019, Kubyshkina., et al, 2018, Hayakumo., et al, 2012, Srikanth et al, 2013, Ameyaroy., et al, 2021, Huth., et al, 2007, Gusiyska e Kisselova, 2010); e na forma gasosa (Saglam., et al, 2019, Yılmaz., et al, 2013, William C Domb, 2014, Rapone., et al, 2020., Dengizek., et al, 2019.…”

Efficacy of adjunctive use of diacerein local delivery in the management of moderate chronic periodontitis: a double-blind randomized controlled trial

“…This therapeutic intervention applies various anti-inflammatory and antibiotic drugs (e.g. Nonsteroidal anti-inflammatory drug (NSAIDs)), providing better treatment outcomes and less undesirable effects (13). Diacerein, an anthraquinone symptomatic drug, provides high permeability, low solubility and is typically prescribed to treat osteoarthritis, was recently proposed as a potential candidate for the treatment of periodontal diseases (14,15).…”